A phase II, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HP184 at 100, 200 and 400 mg doses administered orally once daily for twenty-four weeks in adult subjects with chronic spinal cord injury (CSCI)
- Registry ID
- EUCTR2004-000763-98
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Aventis Pharmaceuticals Inc.
- Start date
- 2004-11-25
- Completion date
- 2005-12-31
- Last update
- 2026-08-16
Conditions
- Chronic spinal cord injury
Summary
To evaluate the effect of HP184 as compared to placebo on total motor score of American Spinal Injury Association (ASIA) manual motor test at Week 24 in subjects with CSCI.
Locations
View on source registry